CV Therapeutics has been granted FDA approval and for the US product launch of its 1000mg Ranexa tablet for the treatment of angina.
Subscribe to our email newsletter
The approved product labeling recommends that Ranexa be initiated at 500mg twice daily and increased to 1000mg as needed, based on clinical symptoms. Prior to the launch of the 1000mg tablet, this meant that patients taking 1000mg had to take four 500mg Ranexa tablets per day. These patients now have the option of taking two 1000mg tablets per day.
“While the 1000mg dose currently represents less than 10% of our business, CV Therapeutics is committed to providing new options that add value for doctors and patients,” said Lewis Stuart, senior vice president, commercial operations.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.